Morphine News and Research RSS Feed - Morphine News and Research

Morphine is an extremely potent opiate analgesic psychoactive drug and is considered to be the prototypical opioid. In clinical medicine, morphine is regarded as the gold standard, or benchmark, of analgesics used to relieve severe or agonizing pain and suffering.
Researchers develop new painkiller as strong as morphine but not addictive

Researchers develop new painkiller as strong as morphine but not addictive

Researchers at Tulane University and Southeast Louisiana Veterans Health Care System have developed a painkiller that is as strong as morphine but isn't likely to be addictive and with fewer side effects, according to a new study in the journal Neuropharmacology. [More]
Educational programs, new clinic policies could significantly reduce level of opioid medication

Educational programs, new clinic policies could significantly reduce level of opioid medication

A recent study showed that medical provider training, new clinic policies and efforts to "taper" opioid use for pain treatment could significantly reduce the level of opioid medication that patients used -- a limited but positive step for a nation enmeshed in opioid use, abuse and overdose deaths. [More]
Opioid medication does not improve physical function in patients with neuropathic pain

Opioid medication does not improve physical function in patients with neuropathic pain

Opioids such as morphine, codeine and Tylenol 3 can be effective for treating pain, however, a new University of Alberta study finds that patients with neuropathic pain taking opioids report no improvements in physical functioning compared to those who were not prescribed opioids. [More]
Long-term use of opioids increases risk of new-onset depression

Long-term use of opioids increases risk of new-onset depression

Opioids may cause short-term improvement in mood, but long-term use imposes risk of new-onset depression, a Saint Louis University study shows. [More]
Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet submits NDA for ARYMO ER (morphine sulfate) extended-release tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate. [More]
Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company. [More]
Motivational interviewing helps curb prescription opioid abuse among older adults with chronic pain

Motivational interviewing helps curb prescription opioid abuse among older adults with chronic pain

Prescription opioid abuse has reached epidemic proportions, with more than half of patients being treated for chronic pain reportedly misusing their medication at some point. [More]
Columbia University data scientists create world's first catalog of therapeutic venom

Columbia University data scientists create world's first catalog of therapeutic venom

What doesn't kill you could cure you. A growing interest in the therapeutic value of animal venom has led a pair of Columbia University data scientists to create the first catalog of known animal toxins and their physiological effects on humans. [More]

Medical researchers use social media to study harmful side effects of narcotics medication

Harnessing the power of social media, medical researchers have sifted through more than two billion tweets and online posts to study the harmful side effects of narcotics medication taken for chronic pain. [More]
FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin. [More]
MSU professor finds surprising results about drug use behaviors

MSU professor finds surprising results about drug use behaviors

Conducting an economic analysis of drug use is a particularly difficult endeavor, but for Michigan State University professor and economist Siddharth Chandra, it just meant taking a look at the history books. [More]
University of Leicester awarded BBSRC grant to explore three key areas that impact human health

University of Leicester awarded BBSRC grant to explore three key areas that impact human health

The University of Leicester has been awarded over £1.5 million in order to advance knowledge and understanding in three key areas that impact on health. [More]

Prescription opioids overprescribed in some regions of British Columbia, UBC study finds

Strong painkillers known as prescription opioids appear to be overprescribed in some regions of British Columbia (B.C.), resulting in higher rates of overdose and death, according to a new study from UBC. [More]
FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

FDA approves Endo’s BELBUCA (buprenorphine) buccal film for use in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
Drug that relieves opioid-induced constipation may help some cancer patients live longer

Drug that relieves opioid-induced constipation may help some cancer patients live longer

Patients with advanced cancers who took a drug designed to relieve constipation caused by pain killers lived longer and had fewer reports of tumor progression than cancer patients who did not receive the drug, according to results presented October 27 at the 2015 meeting of the American Society of Anesthesiologists in San Diego. This is the first study in humans to associate opioid blockade with improved survival. [More]
New research shows nicotine increases codeine-induced analgesia

New research shows nicotine increases codeine-induced analgesia

According to new research in rat models, nicotine use over time increases the speed that codeine is converted into morphine within the brain, by increasing the amount of a specific enzyme. It appears smokers' brains are being primed for a bigger buzz from this common pain killer - which could put them at a higher risk for addiction, and possibly even overdose. [More]
BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII). [More]
AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. [More]

New guideline on the use of prescription medications for treatment of opioid addiction

Medications play an important role in managing patients with opioid use disorders, but there are not enough physicians with the knowledge and ability to use these often-complex treatments. [More]
Premature infants in intensive care units exposed to a great deal of pain

Premature infants in intensive care units exposed to a great deal of pain

Premature infants receiving intensive care are exposed to a great deal of pain, and this pain causes damage to the child. Despite this half of the infants admitted to neonatal intensive units will not receive any pain relief, according to a new European study published today in The Lancet Respiratory Medicine. [More]
Advertisement
Advertisement